KONINKLIJKE PHILIPS N.V. (20240344149). PERSONALIZATION IN PROSTATE CANCER BY USE OF THE PROSTATE CANCER PDE4D7 KNOCK-DOWN SCORE simplified abstract
Contents
PERSONALIZATION IN PROSTATE CANCER BY USE OF THE PROSTATE CANCER PDE4D7 KNOCK-DOWN SCORE
Organization Name
Inventor(s)
Ralf Dieter Hoffman of BRUEGGEN (DE)
George Baillie of GLASGOW (GB)
PERSONALIZATION IN PROSTATE CANCER BY USE OF THE PROSTATE CANCER PDE4D7 KNOCK-DOWN SCORE - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240344149 titled 'PERSONALIZATION IN PROSTATE CANCER BY USE OF THE PROSTATE CANCER PDE4D7 KNOCK-DOWN SCORE
The invention pertains to a method for predicting the response of a prostate cancer patient to radiotherapy by analyzing gene expression profiles of specific genes.
- Determining gene expression profiles of three or more PDE4D7 knockdown genes in a biological sample from the patient.
- Predicting the radiotherapy response based on the gene expression profiles of the selected genes.
- The radiotherapy can be radical or salvage radiotherapy.
Potential Applications: This technology can be used in personalized medicine to tailor radiotherapy treatment for prostate cancer patients based on their gene expression profiles.
Problems Solved: This method helps in predicting the response of prostate cancer patients to radiotherapy, allowing for more targeted and effective treatment.
Benefits: Improved treatment outcomes for prostate cancer patients. Personalized approach to radiotherapy based on individual gene expression profiles.
Commercial Applications: This technology can be valuable for healthcare providers, pharmaceutical companies, and research institutions involved in prostate cancer treatment and personalized medicine.
Questions about the technology: 1. How does this method compare to traditional methods of predicting radiotherapy response in prostate cancer patients? 2. What are the potential implications of using gene expression profiles for treatment decisions in prostate cancer patients?
Frequently Updated Research: Stay updated on the latest research on gene expression profiling in prostate cancer treatment to enhance the predictive accuracy of radiotherapy responses.
Original Abstract Submitted
the invention relates to a method of predicting a response of a prostate cancer subject to radiotherapy, comprising determining or receiving the result of a determination of a gene expression profile for each of three or more pde4d7 knockdown differentially expressed genes selected from the group consisting of: acpp, ar, cdh1, ehf, etv1, folh1, foxa1, hoxb13, klk2, klk3, maoa, mlh1, mme, myo6, naaladl2, nkx3-1, nqo1, nrp1, slc45a3, spdef, atm, atr, brca1, br-ca2, cdk12, fanca, mre11 and palb2, said gene expression profiles being determined in a biological sample obtained from the subject, and determining the prediction of the radiotherapy response based on the gene expression profiles for the three or more pde4d7 knockdown genes, wherein the radiotherapy is radical radiotherapy or salvage radiotherapy.
